Changes in glucose-induced plasma active glucagon-like peptide-1 levels by co-administration of sodium–glucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors in rodents

Journal of Pharmacological Sciences

Volumn 132, Issue 4, 2016, Pages 255-261

  Oguma, Takahiro ^a,b   Kuriyama, Chiaki ^a   Nakayama, Keiko ^a   Matsushita, Yasuaki ^a   Hikida, Kumiko ^a   Tsuda Tsukimoto, Minoru ^a   Saito, Akira ^a   Arakawa, Kenji ^a   Ueta, Kiichiro ^a   Shiotani, Masaharu ^a   Minami, Masabumi ^b  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Canagliflozin; Combination treatment; DPP4 inhibitor; Glucagon like peptide 1; SGLT2 inhibitor

Indexed keywords

1 (BETA DEXTRO GLUCOPYRANOSYL) 4 CHLORO 3 [5 (6 FLUORO 2 PYRIDYL) 2 THIENYLMETHYL]BENZENE; 2 CYANO 1 [4 (MORPHOLINOCARBONYL)CYCLOCYCLOHEXYLAMINO]ACETYLPYRROLIDINE; CANAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; METFORMIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SODIUM GLUCOSE COTRANSPORTER INHIBITOR; TA 1887; TENELIGLIPTIN; TOFOGLIFLOZIN; UNCLASSIFIED DRUG; 3-(4-(4-(3-METHYL-1-PHENYL-1H-PYRAZOL-5-YL)PIPERAZIN-1-YL)PYRROLIDIN-2-YLCARBONYL)THIAZOLIDINE; ANTIDIABETIC AGENT; MONOSACCHARIDE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; TA-3404; THIAZOLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; GLYCEMIC CONTROL; HORMONE RELEASE; IC50; MALE; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; FISCHER 344 RAT; GLUCOSE TOLERANCE TEST; MOUSE;

ANIMALS; CANAGLIFLOZIN; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; MONOSACCHARIDES; PYRAZOLES; PYRIDINES; RATS; RATS, INBRED F344; SITAGLIPTIN PHOSPHATE; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2; THIAZOLIDINES;

EID: 85006817637     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1016/j.jphs.2016.10.006     Document Type: Article

References (18)

1. (1) Wright, E.M., Loo, D.D., Hirayama, B.A., Biology of human sodium glucose transporters. Physiol Rev 91 (2011), 733–794.
2. (2) Liang, Y., Arakawa, K., Ueta, K., Matsushita, Y., Kuriyama, C., Martin, T., et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One, 7, 2012, e30555.
3. (3) Polidori, D., Sha, S., Mudaliar, S., Ciaraldi, T.P., Ghosh, A., Vaccaro, N., et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care 36 (2013), 2154–2161.
4. (4) Meier, J.J., Nauck, M.A., Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes Metab Res Rev 21 (2005), 91–117.
5. (5) Zambrowicz, B., Ding, Z.M., Ogbaa, I., Frazier, K., Banks, P., Turnage, A., et al. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes. Clin Ther 35 (2013), 273–285.
6. (6) Oguma, T., Kuriyama, C., Nakayama, K., Matsushita, Y., Yoshida, K., Kiuchi, S., et al. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats. J Pharmacol Sci 127 (2015), 456–461.
7. (7) Oguma, T., Nakayama, K., Kuriyama, C., Matsushita, Y., Yoshida, K., Hikida, K., et al. Intestinal sodium glucose cotransporter 1 inhibition enhances glucagon-like peptide-1 secretion in normal and diabetic rodents. J Pharmacol Exp Ther 354 (2015), 279–289.
8. (8) Cho, Y.M., Kieffer, T.J., New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser. Diabetologia 54 (2011), 219–222.
9. (9) Kobayashi, K., Forte, T.M., Taniguchi, S., Ishida, B.Y., Oka, K., Chan, L., The db/db mouse, a model for diabetic dyslipidemia: molecular characterization and effects of Western diet feeding. Metabolism 49 (2000), 22–31.
10. (10) Kirino, Y., Sato, Y., Kamimoto, T., Kawazoe, K., Minakuchi, K., Nakahori, Y., Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats. J Endocrinol 200 (2009), 53–61.
11. (11) Yasuda, N., Inoue, T., Nagakura, T., Yamazaki, K., Kira, K., Saeki, T., et al. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 298 (2002), 779–784.
12. (12) Invokana (canagliflozin) Tablets, PHARMACOLOGY REVIEW(S) (APPLICATION NUMBER:204042Orig1s000) [Internet]. U.S. Food and Drug Administration. [cited 2016 Aug 26] Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000PharmR.pdf.
13. (13) Suzuki, M., Honda, K., Fukazawa, M., Ozawa, K., Hagita, H., Kawai, T., et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther 341 (2012), 692–701.
14. (14) Nomura, S., Sakamaki, S., Hongu, M., Kawanishi, E., Koga, Y., Sakamoto, T., et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 53 (2010), 6355–6360.
15. (15) Nomura, S., Yamamoto, Y., Matsumura, Y., Ohba, K., Sakamaki, S., Kimata, H., et al. Novel indole-N-glucoside, TA-1887 as a sodium glucose cotransporter 2 inhibitor for treatment of type 2 diabetes. ACS Med Chem Lett 5 (2013), 51–55.
16. (16) Kuriyama, C., Xu, J.Z., Lee, S.P., Qi, J., Kimata, H., Kakimoto, T., et al. Analysis of the effect of canagliflozin on renal glucose reabsorption and progression of hyperglycemia in zucker diabetic fatty rats. J Pharmacol Exp Ther 351 (2014), 423–431.
17. (17) Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., et al. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedeb Arch Pharmacol 385 (2012), 423–436.
18. (18) Powell, D.R., Smith, M., Greer, J., Harris, A., Zhao, S., DaCosta, C., et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther 345 (2013), 250–259.